Frontiers in Oncology | Thoracic Oncology

Original Research

Published on 23 Dec 2021

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy

in Thoracic Oncology

Jiaojiao Suo
Yu Sun
Yan Fu
Weigang Xiu
Xuanwei Zhang
Yan Wang
Jiang Zhu

Frontiers in Oncology

doi 10.3389/fonc.2021.788837

2,788 views
1 citation

Review

Published on 23 Dec 2021

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

in Thoracic Oncology

Miriam Grazia Ferrara
Alessio Stefani
Sara Pilotto
Carmine Carbone
Emanuele Vita
Mariantonietta Di Salvatore
Ettore D’Argento
Ileana Sparagna
Federico Monaca
Giustina Valente

Frontiers in Oncology

doi 10.3389/fonc.2021.792385

5,876 views
5 citations

Original Research

Published on 21 Dec 2021

“How Long Have I Got?” in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question

in Thoracic Oncology

Huiru Guo
Hegen Li
Lihua Zhu
Jiali Feng
Xiange Huang
Jan P. A. Baak

Frontiers in Oncology

doi 10.3389/fonc.2021.761042

200,139 views
27 citations

Original Research

Published on 16 Dec 2021

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC

in Thoracic Oncology

Wufei Chen
Yanqing Hua
Dingbiao Mao
Hao Wu
Mingyu Tan
Weiling Ma
Xuemei Huang
Jinjuan Lu
Cheng Li
Ming Li

Frontiers in Oncology

doi 10.3389/fonc.2021.722106

2,707 views
6 citations

Original Research

Published on 15 Dec 2021

YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma

in Thoracic Oncology

Qiang Xie
Shilei Zhao
Wenzhi Liu
Yanwei Cui
Fengzhou Li
Zhuoshi Li
Tao Guo
Wendan Yu
Wei Guo
Wuguo Deng

Frontiers in Oncology

doi 10.3389/fonc.2021.702491

6,290 views
27 citations

Review

Published on 15 Dec 2021

EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer

in Thoracic Oncology

Sarah Sayed Hassanein
Ahmed Lotfy Abdel-Mawgood
Sherif Abdelaziz Ibrahim

Frontiers in Oncology

doi 10.3389/fonc.2021.766659

9,973 views
31 citations

Review

Published on 15 Dec 2021

KRAS Mutations in Squamous Cell Carcinomas of the Lung

in Thoracic Oncology

Fabian Acker
Jan Stratmann
Lukas Aspacher
Ngoc Thien Thu Nguyen
Sebastian Wagner
Hubert Serve
Peter J. Wild
Martin Sebastian

Frontiers in Oncology

doi 10.3389/fonc.2021.788084

12,860 views
23 citations

Original Research

Published on 14 Dec 2021

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

in Thoracic Oncology

Yong-feng Yu
Luan Luan
Fan-fan Zhu
Peng Dong
Li-Heng Ma
Lan-ting Li
Lan Gao
Shun Lu

Frontiers in Oncology

doi 10.3389/fonc.2021.564234

5,004 views
7 citations

Original Research

Published on 14 Dec 2021

An External-Validated Algorithm to Predict Postoperative Pneumonia Among Elderly Patients With Lung Cancer After Video-Assisted Thoracoscopic Surgery

in Thoracic Oncology

Yanping Song
Jingjing Liu
Mingxing Lei
Yanfeng Wang
Qiang Fu
Bailin Wang
Yongxin Guo
Weidong Mi
Li Tong

Frontiers in Oncology

doi 10.3389/fonc.2021.777564

4,177 views
22 citations

Original Research

Published on 14 Dec 2021

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors

in Thoracic Oncology

Paul Takam Kamga
Aurélie Swalduz
Adrien Costantini
Catherine Julié
Jean-François Emile
Maurice Pérol
Virginie Avrillon
Sandra Ortiz-Cuaran
Pierre de Saintigny
Etienne Giroux-Leprieur

Frontiers in Oncology

doi 10.3389/fonc.2021.747692

3,716 views
4 citations

Original Research

Published on 14 Dec 2021

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

in Thoracic Oncology

Lin Wu
Chao Deng
Hui Zhang
Jie Weng
You hua Wu
Shan Zeng
Tie gang Tang
Pei guo Cao
Bo Qiu
Li Zhang

Frontiers in Oncology

doi 10.3389/fonc.2021.769037

3,836 views
5 citations

Original Research

Published on 13 Dec 2021

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

in Thoracic Oncology

Qiao Liu
Xia Luo
Zhen Zhou
Liubao Peng
Lidan Yi
Xiaomin Wan
Chongqing Tan
Xiaohui Zeng

Frontiers in Oncology

doi 10.3389/fonc.2021.745493

5,052 views
4 citations

Original Research

Published on 13 Dec 2021

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis

in Thoracic Oncology

Shuang Sun
Yu Men
Jingjing Kang
Xin Sun
Meng Yuan
Xu Yang
Yongxing Bao
Jianyang Wang
Lei Deng
Wenqing Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.781340

3,569 views
9 citations

Original Research

Published on 10 Dec 2021

CT-Based Radiomics Nomogram for Differentiation of Anterior Mediastinal Thymic Cyst From Thymic Epithelial Tumor

in Thoracic Oncology

Chengzhou Zhang
Qinglin Yang
Fan Lin
Heng Ma
Haicheng Zhang
Ran Zhang
Ping Wang
Ning Mao

Frontiers in Oncology

doi 10.3389/fonc.2021.744021

4,335 views
8 citations

Original Research

Published on 10 Dec 2021

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer

in Thoracic Oncology

Huashan Shi
Kexun Zhou
Jordan Cochuyt
David Hodge
Hong Qin
Rami Manochakian
Yujie Zhao
Sikander Ailawadhi
Alex A. Adjei
Yanyan Lou

Frontiers in Oncology

doi 10.3389/fonc.2021.773958

8,589 views
3 citations

Original Research

Published on 09 Dec 2021

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

in Thoracic Oncology

Szu-Chun Yang
Natalia Kunst
Cary P. Gross
Jung-Der Wang
Wu-Chou Su
Shi-Yi Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.760686

7,562 views
11 citations

Original Research

Published on 09 Dec 2021

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy

in Thoracic Oncology

Won Gun Kwack
Ji-Youn Sung
Seung Hyeun Lee

Frontiers in Oncology

doi 10.3389/fonc.2021.770230

2,619 views
4 citations

Original Research

Published on 09 Dec 2021

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study

in Thoracic Oncology

Suyu Wang
Zhiyuan Zhang
Yang Gu
Xin Lv
Xuan Shi
Meiyun Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.726811

4,370 views
3 citations

Original Research

Published on 08 Dec 2021

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma

in Thoracic Oncology

Zhenying Guo
Li Shen
Ningning Li
Xiaoxiao Wu
Canming Wang
Zheng Gu
Zhongjian Chen
Junping Liu
Weimin Mao
Yuchen Han

Frontiers in Oncology

doi 10.3389/fonc.2021.789244

5,484 views
8 citations

Original Research

Published on 07 Dec 2021

Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram

in Thoracic Oncology

Aihua Wu
Zhigang Liang
Songbo Yuan
Shanshan Wang
Weidong Peng
Yijun Mo
Jing Yang
Yanqing Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.775079

4,349 views
11 citations

Review

Published on 01 Dec 2021

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

in Thoracic Oncology

Karan Seegobin
Umair Majeed
Nathaniel Wiest
Rami Manochakian
Yanyan Lou
Yujie Zhao

Frontiers in Oncology

doi 10.3389/fonc.2021.750657

18,483 views
57 citations

Original Research

Published on 01 Dec 2021

Efficacy of Intraoperative Hypertonic Glucose Solution Administration on Persistent Air Leak After Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Retrospective Case–Control Study

in Thoracic Oncology

Alberto Testori
Gianluca Perroni
Marco Alloisio
Emanuele Voulaz
Veronica Maria Giudici
Umberto Cariboni
Edoardo Bottoni

Frontiers in Oncology

doi 10.3389/fonc.2021.767791

3,619 views
3 citations

Original Research

Published on 30 Nov 2021

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy

in Thoracic Oncology

Hui Yang
Kunlun Wang
Bingxu Li
Shenglei Li
Yan Li
Ling Yuan

Frontiers in Oncology

doi 10.3389/fonc.2021.707041

3,975 views
22 citations

Original Research

Published on 30 Nov 2021

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis

in Thoracic Oncology

Lu Peng
Yihao Tao
Rui Wu
Jing Su
Maoyuan Sun
Yuan Cheng
Zongyi Xie
Jinning Mao
Xiaohui Zhan
Guodong Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.781150

6,852 views
6 citations

1,969 articles

articles

A Retrospective Analysis of the Effect of Anlotinib in Patients With Lung Cancer With or Without Previous Antiangiogenic Therapy

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

“How Long Have I Got?” in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question

A Computed Tomography-Derived Radiomics Approach for Predicting Uncommon EGFR Mutation in Patients With NSCLC

YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma

EGFR-Dependent Extracellular Matrix Protein Interactions Might Light a Candle in Cell Behavior of Non-Small Cell Lung Cancer

KRAS Mutations in Squamous Cell Carcinomas of the Lung

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

An External-Validated Algorithm to Predict Postoperative Pneumonia Among Elderly Patients With Lung Cancer After Video-Assisted Thoracoscopic Surgery

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors

Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1)

PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis

CT-Based Radiomics Nomogram for Differentiation of Anterior Mediastinal Thymic Cyst From Thymic Epithelial Tumor

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer

Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer

Overexpression of Reactive Oxygen Species Modulator 1 Predicts Unfavorable Clinical Outcome in EGFR-Mutant Lung Adenocarcinomas Treated With Targeted Therapy

Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma

Development and Validation of a Scoring System for Early Diagnosis of Malignant Pleural Effusion Based on a Nomogram

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Efficacy of Intraoperative Hypertonic Glucose Solution Administration on Persistent Air Leak After Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Retrospective Case–Control Study

The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy

NFAT as a Biomarker and Therapeutic Target in Non–Small Cell Lung Cancer–Related Brain Metastasis